Navigation Links
Vion Pharmaceuticals Presents Updated Clinical Data from a Phase II,trial of Cloretazine (VNP40101M) in Patients with Relapsed or,Refractory Small Cell Lung Cancer

NEW HAVEN, Conn., June 04, 2007 /PRNewswire-FirstCall/ -- VION PHARMACEUTICALS, INC. announced that it presented updated clinical data in a poster session at the 43rd Annual Meeting of The American Society of Clinical Oncology (ASCO) on its lead anticancer agent Cloretazine(R) (VNP40101M) as a single agent in a Phase II trial in patients with relapsed or refractory small cell lung cancer.

The Phase II trial evaluates Cloretazine(R) (VNP40101M) in two separate subpopulations of small cell lung cancer: (i) sensitive relapse disease and (ii) refractory disease. Sensitive relapse disease is defined as relapse after three months of first-line therapy and refractory disease is defined as relapse within three months of first-line therapy. Data are presented on a total of 48 evaluable patients: (i) 20 patients in the sensitive relapse arm and (ii) 28 patients in the refractory arm.

Patients on the trial initially received 125 mg/m2 of Cloretazine(R) (VNP40101M) weekly for three weeks, every six weeks. This dose was later reduced by protocol amendment to 100 mg/m2 weekly for three weeks every six weeks due to the incidence of grade 3 and 4 thrombocytopenia at the initial dose level.

Of the 20 evaluable patients on the sensitive relapse arm, there have been 6 patients with partial response and one patient awaiting confirmation of response (overall, 35% response rate), and 3 patients have stable disease. Four of 13 sensitive relapse patients responded at the 125 mg/m2 dose level and 3 of 7 sensitive relapse patients responded at the 100 mg/m2 dose level. Of the 28 patients with refractory disease treated with Cloretazine(R) (VNP40101M), 1 patient achieved a partial response and 3 patients have demonstrated stable disease.

A total of 55 patients were evaluable for toxicity. Grade 3 and 4 thrombocytopenia was observed in 14 of 31 patients (45%) at the 125 mg/m2 dose level. Thrombocytopenia was su
'"/>




Page: 1 2 3 4

Related medicine technology :

1. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
2. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
3. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
4. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
5. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
6. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
7. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
8. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
9. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
10. Cyclacel Pharmaceuticals Announces Results of Phase II Seliciclib Combination Studies
11. Arisaph Pharmaceuticals Announces Results of its Potent Smart DPP-4 Inhibitor, ARI-2243, at the ADA
Post Your Comments:
(Date:12/4/2009)EMERYVILLE, Calif., Dec. 4 Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX ) today announced that it will host an investor teleconference and webcast. Principal investigators will discuss the data present
(Date:12/4/2009)STREAMWOOD, Ill., Dec. 4 Shared Imaging, LLC, an independent provider of CT, MRI and PET/CT systems and service programs for hospitals and healthcare providers, is excited to announce it has received
(Date:12/4/2009)LAKE FOREST, Ill., Dec. 4 Hospira, Inc. (NYSE: HSP ), a leading global specialty pharmaceutical and medication delivery company, today announced the launch of its next-generation 50 mL and 100 mL V
Breaking Medicine Technology:Onyx Pharmaceuticals to Host American Society of Hematology (ASH) Investor Teleconference 2Shared Imaging Earns The Joint Commission's Accreditation for Ambulatory Health Care 2Hospira Expands VisIV(TM) Portfolio to Offer Complete Range of Environmentally Friendly I.V. Containers 2Hospira Expands VisIV(TM) Portfolio to Offer Complete Range of Environmentally Friendly I.V. Containers 3Hospira Expands VisIV(TM) Portfolio to Offer Complete Range of Environmentally Friendly I.V. Containers 4Arizona Pain Specialists Contend Recent Vertebroplasty Studies are Misleading 3A Studies Actually Show it is Effective at Reducing Pain 53944 1Arizona Pain Specialists Contend Recent Vertebroplasty Studies are Misleading 3A Studies Actually Show it is Effective at Reducing Pain 53944 2Arizona Pain Specialists Contend Recent Vertebroplasty Studies are Misleading 3A Studies Actually Show it is Effective at Reducing Pain 53944 3Slide Into Debt Could Bring Wider Waistline 53941 1Slide Into Debt Could Bring Wider Waistline 53941 2AlloSource Chosen as Healthcare Finalist in 2009 Top Companies 53937 1AlloSource Chosen as Healthcare Finalist in 2009 Top Companies 53937 2AlloSource Chosen as Healthcare Finalist in 2009 Top Companies 53937 3
...s to be Presented at the North American Menopause ... Meeting, EMERYVILLE, Calif., Sept. 25 Bionovo, ...a presentation on their new drug,candidate, VG101,... Annual,Meeting of the North American Menopause So...r. Mary Tagliaferri, president and chief medical,o...
...ance of cleaning floor drains often underestimated...ation protocols, ATLANTA, Sept. 24 Recent media ...rs concerned about food safety. As a result of the...tailers, and food service,companies are reviewing ...ls in order to reduce the risk of food contaminati...
Other Medicine Technology:Bionovo's VG101 Shows Greater Efficacy Than Estrogen in the Treatment of Vaginal Dryness 2Bionovo's VG101 Shows Greater Efficacy Than Estrogen in the Treatment of Vaginal Dryness 3Chemstar Corporation Announces a New Powerful, One-Step Product That Effectively Controls Listeria, Salmonella, E. coli and Fly Larvae in Floor Drains 2Chemstar Corporation Announces a New Powerful, One-Step Product That Effectively Controls Listeria, Salmonella, E. coli and Fly Larvae in Floor Drains 3
(Date:12/5/2009)--In Youngest Babies, This Type of Blood Cancer Is Most Challenging-- ,, PHILADELPHIA and NEW ORLEANS, Dec. 5 Pediatric oncologists have identified specific genes, dubbed partner genes, that fuse w
(Date:12/5/2009)Midbrook,s advanced Technology Center helps companies develop and test their cleaning processes. The technology available to the lab allows it to work in a variety of industries and solve problems for
(Date:12/4/2009)PALO ALTO, Calif., Dec. 4 Varian Medical Systems (NYSE: VAR ) announced today that its Board of Directors has set the regular 2010 Annual Meeting of Stockholders for February 11, 2010 with a record
(Date:12/4/2009)PEMBROKE, Bermuda, Dec. 4 Allied World Assurance,Company Holdings, Ltd (NYSE: AWH ) today announced that Scott Carmilani,President and Chief Executive Officer, and Jack Sennott, Executive Vice,Pres
(Date:12/4/2009)MADISON HEIGHTS, Mich., Dec. 4 The Editorial Advisory and Securities Review Committee of BetterInvesting Magazine today announced Allergan, Inc. (NYSE: AGN ) as its February 2010 "Stock to Stud
Breaking Medicine News(10 mins):Health News:New Gene Findings Will Help Guide Treatment in Infant Leukemia 2Health News:New Gene Findings Will Help Guide Treatment in Infant Leukemia 3Health News:New Gene Findings Will Help Guide Treatment in Infant Leukemia 4Health News:Midbrook Lab Testing Provides Results for Cleaning Process Develop and Verification 2Health News:Midbrook Lab Testing Provides Results for Cleaning Process Develop and Verification 3Health News:Varian Medical Systems Schedules Annual Stockholder Meeting in Palo Alto 2Health News:Allied World to Present at the 2009 Goldman Sachs U.S. Financial Services Conference 2Health News:BetterInvesting Magazine Releases February Stock to Study and Undervalued Stock Choicesfor Investors' Informational and Educational Use 2
...ere Wednesday, taking the toll from mosquito-borne...ficials maintained that the number of cases had dr...anj in Uttar Pradesh, died at the All India Instit...were fluctuations in the platelet count," said D.K...
...ng to yoga to keep its troopers fighting fit. When...achar-Mizoram (TCM) frontier of BSF, saw his "boys...oga therapy. "We have already introduced yoga...t himself, told IANS. Psychiatrist John M. Ra...
...replacement therapy could help people who want qui...t the Otto Wagner Hospital// in Vienna enrolled 68...tine-replacement therapy, reported the online edit...pretty well. Just over half the smokers on nicotin...
...cer in UK are now eliglble for annual MRI (Magneti...-49//. Studies show that this disease which kills ...ected by the scan in younger women.Around 5% of th...sible for it(BRCA1 and BRCA2). Those who test posi...
...h polio in spite of receiving 9 doses of the polio...o can be prevented by 4-10 doses of the vaccine//....lled Jannat. “Earlier she used to roam around ...ing to the state health department records, Jannat...
...ients showed evidence of a chronic condition six m...ing drug-induced liver// injury (DILI). Antimicrob...ommon prescription medications implicated in indio...al centers and a data-coordinating center, and it ...
Other Medicine News:Health News:13-Year-Old Boy Is Latest Dengue Victim; Delhi Toll 47 2Health News:Some Prescriptions Can Lead to Chronic Drug-Induced Liver Injury 2
ENDO GIA ROTICULATOR™ (Single Use Loading Units (SULU's) with Titanium Staples)
...as application in multiple open or other minimally...ection, and/or creation of anastomoses and can be ...als such as bovine pericardium., ,Staplers may be.... Different cartridges of the same size can be int...
ENDOPATH ETS Compact-Flex45 Articulating Linear Cutters
...ains 20 titanium clips in the ML and M sizes, and ...designed for introduction and use through all appr...ger sized trocar sleeves with the use of a convert...er through the trocar sleeve, press the loading tr...
Medicine Products: